<DOC>
	<DOCNO>NCT00171587</DOCNO>
	<brief_summary>The objective study ass safety , tolerability , dose limit toxicity , maximum tolerate dose vatalanib administer orally daily combination capecitabine patient advance cancer . The study also design determine effect vatalanib pharmacokinetics capecitabine effect capecitabine pharmacokinetics vatalanib , describe anti-tumor activity combination regimen .</brief_summary>
	<brief_title>Study Safety , Tolerability , Pharmacokinetics , Anti-tumor Effects Vatalanib Combination With Capecitabine Patients With Advanced Cancer</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>Patients histologically confirm advanced cancer refractory standard therapy standard therapy exist ( dose escalation phase study ) Patients histologically confirm metastatic solid tumor colorectal cancer present metastatic disease receive four prior chemotherapy metastatic disease ( dose expansion phase study ) Measurable nonmeasurable disease determine Response Evaluation Criteria Solid Tumors ( RECIST ) criteria Age &gt; = 18 year old Karnofsky Performance Status ( KPS ) &gt; = 70 Absolute neutrophil count ( ANC ) &gt; = 1.5 x 10^9/L Hemoglobin ( Hgb ) &gt; = 9 g/dl Platelets &gt; = 100 x 10^9/L Aspartate aminotransferase ( AST/SGOT ) alanine aminotransferase ( ALT/SGPT ) &lt; = 3.0 x upper limit normal ( ULN ) Serum bilirubin &lt; = 1.5 x ULN Serum creatinine &lt; = 1.5 x ULN 24hour creatinine clearance &gt; = 50 ml/min Total urinary protein 24hour urine collection &lt; = 500 mg Life expectancy great 3 month Written inform consent obtain accord local guideline Patients acute chronic leukemia , lymphoma , multiple myeloma Patients know bone marrow involvement tumor Patients history primary central nervous system tumor brain metastasis Prior allogeneic , syngeneic , autologous bone marrow transplant stem cell transplant Patients two prior chemotherapy regimens metastatic disease ( dose escalation phase study ) Patients receive chemotherapy less 4 week ( 6 week nitrosoureas mitomycinC 2 week vincristine ) prior entry study recover side effect therapy Patients receive immunotherapy within 2 week recover side effect therapy Patients receive radiotherapy within 2 week recover side effect therapy . The site radiotherapy site measurable disease . Major surgery within 2 week prior entry study patient recover side effect therapy Patients receive investigational drug within 4 week prior entry study recover side effect therapy Patients pregnant breast feeding , adult reproductive potential employ effective method birth control . Oral , implantable , injectable contraceptive consider effective method birth control study . ( Women childbearing potential must negative serum pregnancy test 48 hour prior administration chemotherapy ) . Concurrent severe and/or uncontrolled medical disease ( i.e. , uncontrolled diabetes , congestive cardiac failure , myocardial infarction within 6 month , poorly control hypertension , history labile hypertension , history poor compliance antihypertensive regimen , chronic renal disease , active uncontrolled infection ) could compromise participation study Acute chronic liver disease ( e.g. , hepatitis , cirrhosis ) Confirmed diagnosis HIV infection Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption PTK787/ZK 222584 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , bowel obstruction , inability swallow capsules/tablets ) Patients take Coumadin ( warfarin sodium ) Patients unwilling unable comply protocol Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Metastatic solid tumor</keyword>
	<keyword>PTK787/ZK 222584</keyword>
	<keyword>Vatalanib</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>VEGF ( vascular endothelial growth factor )</keyword>
	<keyword>Histologically confirm metastatic solid tumor</keyword>
</DOC>